Literature DB >> 27923195

Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.

Amer M Zeidan1, Minoo Battiwalla2, Deborah Berlyne3, Thomas Winkler4.   

Abstract

Patients with acquired and inherited bone marrow failure syndromes (BMFS) have ineffective hematopoiesis due to impairments of the hematopoietic stem cell compartment. Common manifestations of BMFS include varying degrees of peripheral blood cytopenias and, sometimes, progression to acute myelogenous leukemia. Research efforts have been made all over the world to improve understanding of the pathogenesis of these diseases and their clinical implications. The Aplastic Anemia and MDS International Foundation (AAMDSIF) is an independent nonprofit organization whose mission is to help patients and family members cope with BMFS. Here, we summarize recent scientific discoveries in several BMFS that were presented at the fifth International Bone Marrow Failure Disease Scientific Symposium 2016 that AAMDSIF sponsored on March 17-18, 2016, in Rockville, Maryland.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aplastic anemia; Bone marrow failure; Hematopoietic stem cell transplantation; Immunobiology; Myelodysplastic syndromes; Novel therapies

Mesh:

Year:  2016        PMID: 27923195      PMCID: PMC7731993          DOI: 10.1016/j.leukres.2016.11.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Authors:  Valeria Santini; Antonio Almeida; Aristoteles Giagounidis; Stefanie Gröpper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo Del Cañizo; Norbert Gattermann; Keiya Ozawa; Alberto Risueño; Kyle J MacBeth; Jianhua Zhong; Francis Séguy; Albert Hoenekopp; C L Beach; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

2.  HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders.

Authors:  Alice Bertaina; Pietro Merli; Sergio Rutella; Daria Pagliara; Maria Ester Bernardo; Riccardo Masetti; Daniela Pende; Michela Falco; Rupert Handgretinger; Francesca Moretta; Barbarella Lucarelli; Letizia P Brescia; Giuseppina Li Pira; Manuela Testi; Caterina Cancrini; Nabil Kabbara; Rita Carsetti; Andrea Finocchi; Alessandro Moretta; Lorenzo Moretta; Franco Locatelli
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

3.  Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

Authors:  Tetsuichi Yoshizato; Bogdan Dumitriu; Kohei Hosokawa; Hideki Makishima; Kenichi Yoshida; Danielle Townsley; Aiko Sato-Otsubo; Yusuke Sato; Delong Liu; Hiromichi Suzuki; Colin O Wu; Yuichi Shiraishi; Michael J Clemente; Keisuke Kataoka; Yusuke Shiozawa; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Yasunobu Nagata; Takamasa Katagiri; Ayana Kon; Masashi Sanada; Phillip Scheinberg; Satoru Miyano; Jaroslaw P Maciejewski; Shinji Nakao; Neal S Young; Seishi Ogawa
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

4.  Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Authors:  Sujith Samarasinghe; Katherine Clesham; Simona Iacobelli; Giulia Sbianchi; Cora Knol; Rose-Marie Hamladji; Gerard Socié; Mahmoud Aljurf; Mickey Koh; Henrik Sengeloev; Jean-Hugues Dalle; Stephen Robinson; Maria Teresa Van Lint; Constantijn J M Halkes; Dietrich Beelen; Ghulam J Mufti; John Snowden; Didier Blaise; Regis Peffault de Latour; Judith Marsh; Carlo Dufour; Antonio M Risitano
Journal:  Am J Hematol       Date:  2018-11-25       Impact factor: 10.047

5.  Danazol Treatment for Telomere Diseases.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Delong Liu; Angélique Biancotto; Barbara Weinstein; Christina Chen; Nathan Hardy; Andrew D Mihalek; Shilpa Lingala; Yun Ju Kim; Jianhua Yao; Elizabeth Jones; Bernadette R Gochuico; Theo Heller; Colin O Wu; Rodrigo T Calado; Phillip Scheinberg; Neal S Young
Journal:  N Engl J Med       Date:  2016-05-19       Impact factor: 91.245

6.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Authors:  A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

7.  Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.

Authors:  Austin G Kulasekararaj; Jie Jiang; Alexander E Smith; Azim M Mohamedali; Syed Mian; Shreyans Gandhi; Joop Gaken; Barbara Czepulkowski; Judith C W Marsh; Ghulam J Mufti
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

8.  Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Authors:  Stanley Chun-Wei Lee; Heidi Dvinge; Eunhee Kim; Hana Cho; Jean-Baptiste Micol; Young Rock Chung; Benjamin H Durham; Akihide Yoshimi; Young Joon Kim; Michael Thomas; Camille Lobry; Chun-Wei Chen; Alessandro Pastore; Justin Taylor; Xujun Wang; Andrei Krivtsov; Scott A Armstrong; James Palacino; Silvia Buonamici; Peter G Smith; Robert K Bradley; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.